Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine

Anti-Cancer Drugs

Volumn 19, Issue 4, 2008, Pages 381-389

  Park, Sang Ki ^a   Kang, Hyerim ^a   Kwon, Chul Hoon ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Anilinoacridine; Anticancer; Apoptosis; Caspase; P53; Poly(adp ribose) polymerase 1, topoisomerase

Indexed keywords

2 [[4 [4 (ACRIDIN 9 YLAMINO)PHENYLTHIO]PHENYL](2 HYDROXYETHYL)AMINO]ETHAN 1 OL; 3 [[4 [4 (ACRIDIN 9 YLAMINO)PHENYLTHIO]PHENYL](3 HYDROXYPROPYL)AMINO]PROPAN 1 OL; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; 9 ANILINOACRIDINE DERIVATIVE; AMSACRINE; ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CASPASE INHIBITOR; CK 0402; CK 0403; DNA TOPOISOMERASE (ATP HYDROLYSING); NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; UNCLASSIFIED DRUG; 2 ((4 (4 (ACRIDIN 9 YLAMINO)PHENYLTHIO)PHENYL)(2 HYDROXYETHYL)AMINO)ETHAN 1 OL; 2-((4-(4-(ACRIDIN-9-YLAMINO)PHENYLTHIO)PHENYL)(2-HYDROXYETHYL)AMINO)ETHAN-1-OL; 3 ((4 (4 (ACRIDIN 9 YLAMINO)PHENYLTHIO)PHENYL)(3 HYDROXYPROPYL)AMINO)PROPAN 1 OL; 3-((4-(4-(ACRIDIN-9-YLAMINO)PHENYLTHIO)PHENYL)(3-HYDROXYPROPYL)AMINO)PROPAN-1-OL; ACRIDINE DERIVATIVE; CASPASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SULFIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; EMBRYO; ENZYMATIC ASSAY; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MOUSE EMBRYO; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; FIBROBLASTS; HUMANS; MICE; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; SULFIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 47949111859     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f9adb2     Document Type: Article

References (28)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3:430-440.
2. Giles GI, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 2005; 1:383-394.
3. Cassileth PA, Gale RP. Amsacrine: a review. Leuk Res 1986; 10: 1257-1265.
4. Ahmann FR, Meyskens FL Jr, Jones SE, Bukowski RM, Saiers JH, Ryan DH, et al. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. Cancer Treat Rep 1983; 67:697-700.
5. Demeunynck M, Charmantray F, Martelli A. Interest of acridine derivatives in the anticancer chemotherapy. Curr Pharm Des 2001; 7:1703-1724.
6. Denny WA. Acridine derivatives as chemotherapeutic agents. Curr Med Chem 2002; 9:1655-1665.
7. Marshall B, Darkin S, Ralph RK. Evidence that m-AMSA induces topoisomerase action. FEBS Lett 1983; 161:75-78.
8. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 1984; 81:1361-1365.
9. Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed MR, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993; 7:659-670.
10. Solary E, Bertrand R, Kohn KW, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81:1359-1368.
11. 2 Cell cycle arrest. Cancer Res 2004; 64:4487-4497.
12. Wurzer G, Herceg Z, Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to upregulation of the multidrug resistance gene product P-glycoprotein. Cancer Res 2000; 60:4238-4244.
13. Moreland N, Finlay GJ, Dragunow M, Holdaway KM, Baguley BC. Cellular responses to methyl-N-[4-9-(acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells. Eur J Cancer 1997; 33:1668-1676.
14. Baguley BC, Wakelin LP, Jacintho JD, Kovacic P. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? Curr Med Chem 2003; 10:2643-2649.
15. Kettle AJ, Robertson IG, Palmer BD, Anderson RF, Patel KB, Winterbourn CC. Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Biochem Pharmacol 1992; 44:1731-1738.
16. Chen KM, Sun YW, Tang YW, Sun ZY, Kwon CH. Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines. Mol Pharm 2005; 2: 118-128.
17. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999; 35: 1517-1525.
18. Park SK, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol 2003; 23:4959-4971.
19. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 2000; 60:4010-4015.
20. Morris SM, Domon OE, McGarrity LJ, Chen JJ, Casciano DA. Programmed Cell death and mutation induction in AHH-1 human lymphoblastoid cells exposed to m-amsa. Mutat Res 1995; 329:79-96.
21. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004; 23:1283-1290.
22. Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005; 331:859-867.
23. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001; 84:106-112.
24. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999; 20:199-203.
25. Lemke K, Poindessous V, Skladanowski A, Larsen AK. The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 2004; 66:1035-1042.
26. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, et al. Acridine derivatives activate p53 and induce tumor Cell death through Bax. Cancer Biol Ther 2005; 4:893-898.
27. Boulton S, Kyle S, Yalcintepe L, Durkacz BW. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis 1996; 17:2285-2290.
28. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase II beta-mediated dsDNA break required for regulated transcription. Science 2006; 312:1798-1802.